contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vastra-hamnen-market-focus-gabather-key-shareholders-show-support

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Gabather

A directed share issue adds MSEK 4.2 before costsFirst patient enrolment expected as next triggerWe keep our fair value of SEK 0.06 per shareGabather has carried out a directed share issue of...

<div class="mfn-body"><ul><li>A directed share issue adds MSEK 4.2 before costs</li><li>First patient enrolment expected as next trigger</li><li>We keep our fair value of SEK 0.06 per share</li></ul><p>Gabather has carried out a directed share issue of approximately MSEK 4.2 with participation from several investors, improving the company’s cash position. Together with earlier warrant exercises and improved cost control, this reduces financial risk and extends the funding runway. Further progress updates on the phase II clinical trial of GT-002 in Denmark are awaited.</p><p>The full report is available <a href="https://www.vhcorp.se/en/services/market-focus/gabather/gabather-key-shareholders-show-support" rel="noopener">here</a>.</p></div><div class="mfn-footer mfn-about mfn-d368094d0583"><p><strong class="mfn-heading-1">About Market Focus</strong></p><hr><p>The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.<br><br>This is a press release from Västra Hamnen Corporate Finance AB.&nbsp;<br>Web:&nbsp;<a href="https://vhcorp.se/" rel="noopener">vhcorp.se</a><br>Twitter:&nbsp;@vhcorp_se&nbsp;(<a href="https://twitter.com/vhcorp_se" rel="noopener">https://x.com/vhcorp_se</a>)</p></div>

Västra Hamnen Market Focus: Gabather: Key shareholders show support

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation

Nordea Bank

Aktionær i Nordea? Det er nemmere end nogensinde at deltage i Nordeas generalforsamling takket være nyt digitalt setup